CHRS insider transaction filings
Coherus Oncology, Inc. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-09. Screen CHRS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-09 | 4 | Satvat Ali J. — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Karachun Rita A — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Newcomer Lee Nisley — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Ryan Michael Lee — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | O'Donnell-Tormey Jill — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Newton Charles W. — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Wahlstrom Mats — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | McMichael Bryan J — Chief Financial Officer | Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · +6 more | EDGAR |
| 2026-06-02 | 4 | Lanfear Dennis M — President & CEO, Director | Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 450,000 (derivative) · Disposition to issuer (D): 500,000 (derivative) · Disposition to issuer (D): 500,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · +12 more | EDGAR |
| 2026-01-26 | 4 | McMichael Bryan J — Chief Financial Officer | Grant/award (A): 112,500 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Lanfear Dennis M — President & CEO, Director | Grant/award (A): 375,000 @ $0 · Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | McMichael Bryan J — Chief Financial Officer | Tax withholding (F): 1,715 @ $1.55 | EDGAR |
| 2026-01-22 | 4 | Lanfear Dennis M — President & CEO, Director | Tax withholding (F): 11,839 @ $1.55 | EDGAR |
| 2025-06-13 | 4 | O'Donnell-Tormey Jill — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Newcomer Lee Nisley — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Ryan Michael Lee — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Karachun Rita A — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Erbez Georgia — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Newton Charles W. — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Satvat Ali J. — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Wahlstrom Mats — Director | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | Wahlstrom Mats — Director | Sale (S): 99,988 @ $0.74 | EDGAR |
| 2025-05-09 | 4 | McMichael Bryan J — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Lanfear Dennis M — President & CEO, Director | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Coherus Oncology, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CHRS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →